Filippi, Massimo http://orcid.org/0000-0002-5485-0479
Capra, Ruggero
Centonze, Diego
Gasperini, Claudio
Patti, Francesco
Perini, Paola
Pozzilli, Carlo
Rocca, Maria A.
Uccelli, Antonio
Trojano, Maria
Funding for this research was provided by:
Roche Italia (Unrestricted educational grant)
Article History
Received: 8 January 2021
Accepted: 11 February 2021
First Online: 20 February 2021
Compliance with ethical standards
:
: M. Filippi is Editor-in-Chief of the Journal of Neurology; received compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA). R. Capra has received received compensation for consulting services and/or speaking activities and/or travel grants from Biogen, Celgene, Genzyme, Novartis, Roche and Sanofi. D. Centonze D.C. is an Advisory Board member of Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva and received honoraria for speaking or consultation fees from Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva. He is also the principal investigator in clinical trials for Bayer Schering, Biogen, Merck Serono, Mitsubishi, Novartis, Roche, Sanofi-Genzyme, and Teva. His preclinical and clinical research was supported by grants from Bayer Schering, Biogen Idec, Celgene, Merck Serono, Novartis, Roche, Sanofi-Genzyme and Teva. C. Gasperini has received funding for invited speaker or travel expenses for attending meetings from Biogen, Genzyme, Merck Serono, Novartis, Roche, Sanofi, and Teva. F. Patti has received personal compensation for speaking and serving on advisory boards from Almirall, Bayer, Biogen, Celgene, Merck, Novartis, Roche, Sanofi, and Teva. P. Perini reports grants and personal fees from Merck Serono, Biogen, Genzyme Sanofi, Teva, Bayer Schering, Novartis and Roche. C. Pozzilli received consulting and lecture fees and research funding and travel grants from Almirall, Bayer, Biogen, Genzyme, Merck Serono, Novartis, Roche and Teva M.A. Rocca received speakers’ honoraria from Bayer, Biogen Idec, Celgene, Genzyme, Merck Serono, Novartis, Roche, and Teva, and receives research support from the MS Society of Canada and Fondazione Italiana Sclerosi Multipla. A. Uccelli received grants and contracts from FISM, Novartis, Fondazione Cariplo, and Italian Ministry of Health; received honoraria or consultation fees from Biogen, Roche, Teva, Merck, Genzyme, and Novartis. M. Trojano received speaker’s honoraria, consulting fees, honoraria in advisory boards, support for attendance of scientific meetings from Meck Serono, Biogen, Novartis, Teva, Roche and Sanofi Genzyme.
: Not applicable.